Justice Department Raises J&J Settlement to $1.8 Billion

0
63

Following Johnson & Johnson’s $158 million resolution with Texas several states have demanded higher payments, leading the U.S. Justice Department to raise its demand to $1.8 billion to settle its claims of false and misleading marketing. Risperdal was initially approved for psychotic disorders, but J&J marketed it for bipolar disorder, dementia, mood and anxiety disorders and other unapproved uses. Other states have indicated potential interest in litigation as well.

Article →                                              Discuss →

***

Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.

***

Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.

Previous articleRisk of Death Five Times Higher With Sleep Meds
Next articleDSM Panels Rife With Conflicts of Interest
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]

LEAVE A REPLY